Who
Christopher Gibson
Director
Company insider
Files Form 4 as: Chief Executive Officer, Recursion Pharmaceuticals; Director, Pacific Biosciences of California.
In numbers
- Trades disclosed
- 847
- Buys
- 0
- Sells
- 97
- Bought
- $0
- Sold
- $41.0M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 20 Apr 2021
- Last trade
- 5 Jun 2026
- Last filed
- 5 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Jun 2026filed 5 Jun 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code C | —40,000 at $0.00 | filing |
| 5 Jun 2026filed 5 Jun 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $145K40,000 at $3.62 | filing |
| 5 Jun 2026filed 5 Jun 2026 | RXRX Recursion Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code C | —40,000 at $0.00 | filing |
| 5 Jun 2026filed 5 Jun 2026 | RXRX Recursion Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code C | —40,000 at $0.00 | filing |
| 5 Jun 2026filed 5 Jun 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code C | —40,000 at $0.00 | filing |
| 5 Jun 2026filed 5 Jun 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $145K40,000 at $3.62 | filing |
| 3 Jun 2026filed 4 Jun 2026 | PACB Pacific Biosciences of Californiaoption or derivative · Life-science tools | SEC FORM 4 Code A | —74,497 at $0.00 | filing |
| 3 Jun 2026filed 4 Jun 2026 | PACB Pacific Biosciences of Californiaoption or derivative · Life-science tools | SEC FORM 4 Code A | —74,497 at $0.00 | filing |
| 22 May 2026filed 27 May 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code C | —40,000 at $0.00 | filing |
| 22 May 2026filed 27 May 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $123K40,000 at $3.08 | filing |
| 22 May 2026filed 27 May 2026 | RXRX Recursion Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code C | —40,000 at $0.00 | filing |
| 22 May 2026filed 27 May 2026 | RXRX Recursion Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code C | —40,000 at $0.00 | filing |
| 22 May 2026filed 27 May 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code C | —40,000 at $0.00 | filing |
| 22 May 2026filed 27 May 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $123K40,000 at $3.08 | filing |
| 15 May 2026filed 19 May 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $69K22,821 at $3.04 | filing |
| 15 May 2026filed 19 May 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $69K22,821 at $3.04 | filing |
| 7 May 2026filed 8 May 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code C | —60,000 at $0.00 | filing |
| 7 May 2026filed 8 May 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $135K40,000 at $3.37 | filing |
| 7 May 2026filed 8 May 2026 | RXRX Recursion PharmaceuticalsBiotechnology | SEC FORM 4 Code G | —20,000 at $0.00 | filing |
| 7 May 2026filed 8 May 2026 | RXRX Recursion Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code C | —60,000 at $0.00 | filing |
The newest 500 lines are listed; the numbers count every line.
News
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Lifted to "Sell" by Wall Street ZenRXRX · dailypolitical.com · 18 Oct 2026Contrasting Recursion Pharmaceuticals (NASDAQ:RXRX) and Oramed Pharmaceuticals (NASDAQ:ORMP)RXRX · dailypolitical.com · 11 Oct 2026
0 headlines in the last 90 days name Christopher Gibson; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.